JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i4.10377ArticleReal-world Clinical Study of Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Staturehttps://artdesignp.com/journal/JCNR/9/4/10.26689/jcnr.v9i4.10377LiuJianhua,ShiJin2025942025-04-29Objective: To investigate the clinical efficacy and safety evaluation of Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH) in the treatment of idiopathic short stature. Methods: A total of 1402 patients were enrolled from March 21, 2024 to January 13, 2025, including 778 males and 624 females, with ages mainly ranging from 5 to 13 years old. Follow-up visits were completed by 488 patients for the first time, 174 patients for the second time, and 81 patients for the third time. All patients were treated with PEG-rhGH (Jin Sai Zeng) as the main therapy after admission. The changes in height information, IGF-1, and thyroid examination results of each patient at the initial diagnosis, 6, 9, and 12 months after treatment were observed and analyzed. Results: There was no statistical difference between the baseline and the initial diagnosis, as well as the second follow-up visit (P < 0.05), while there was a statistical difference between the baseline and the first and third follow-up visits (P > 0.05). There was a statistically significant difference in IGF-1 between the initial diagnosis and the first follow-up visit (P < 0.05), but no statistical difference between the first, second, and third follow-up visits (P > 0.05). Additionally, IGF-1 levels increased with time. There was no statistical difference in TSH between the initial diagnosis and the first, second, and third follow-up visits (P > 0.05). There was a statistical difference in free T3 between the initial diagnosis and the first and second follow-up visits (P<0.05), but no statistical difference between the second and third follow-up visits (P>0.05). There was no statistical difference in free T4 between the initial diagnosis and the first and second follow-up visits (P > 0.05), but there was a statistical difference between the second and third follow-up visits (P < 0.05). Conclusion: PEG-rhGH (Jin Sai Zeng) is significantly effective in improving height and IGF-1 levels in patients with idiopathic short stature.

Ge L, Zhao C, Xu F, et al., 2023, Research Progress on Polyethylene Glycol Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Stature in Children. Modern Clinical Medicine, 49(2): 128–130.

Wang X, Deng Q, Li M, et al., 2024, Clinical Study on the Effect of PEG-rhGH in the Treatment of Children with Idiopathic Short Stature on Growth Rate. Chinese Journal of Clinical Pharmacology, 40(18): 2685–2689.

Feng X, Wang C, 2023, Research Progress on Multi-Omics Biomarkers of Idiopathic Short Stature. International Journal of Pediatrics, 50(11): 746–749.

Song M, Liu H, Wang J, et al., 2024, Diagnostic Value of Combined Detection of Serum Nesfatin-1, IGFBP-3, and FGF-21 in Idiopathic Short Stature. Labeled Immunoassays and Clinical Medicine, 31(4): 658–665.

Zhang D, Cheng W, Zhang L, et al., 2024, Clinical Study on Long-Acting and Short-Acting Recombinant Human Growth Hormone in the Treatment of Children with Idiopathic Short Stature. Chinese Journal of Clinical Pharmacology, 40(15): 2178–2181.

Sun Z, Ma Y, Tian C, 2024, Efficacy and Safety of Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Stature. Chinese Journal of Practical Medicine, 51(21): 101–103.

Zou H, Hu Y, Xiong T, et al., 2023, Clinical Study on Recombinant Human Growth Hormone in the Treatment of Children with Idiopathic Short Stature. Chinese Journal of Clinical Pharmacology, 39(19): 2761–2765.

Gu J, Sun S, Gao X, et al., 2024, Effects of Growth Hormone Combined with Nutritional Therapy on Physical Function Indicators of Children with Idiopathic Short Stature. Chinese Journal of Maternal and Child Health Research, 35(2): 59–63.

Ling R, Wang H, Ding H, 2018, Continuous Nursing Practice for Children with Idiopathic Short Stature. Journal of Clinical Medicine in Practice, 22(16): 93–97.

Zhou Y, Zhang H, Zhu S, 2023, Study on the Correlation Between Serum PCSK9 and FGF-23 Expression and the Occurrence of Idiopathic Short Stature. Youjiang Medical Journal, 51(12): 1096–1101.

Guo Y, Xu S, 2023, Efficacy of Calcium Gluconate Combined with rhGH in the Treatment of Idiopathic Short Stature in Children. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 33(3): 11–14.

Zhu M, Qian W, Lu Y, et al., 2024, Diagnostic Value of Short-Chain Fatty Acids in Children with Idiopathic Short Stature. Laboratory Medicine and Clinic, 21(13): 1860–1863, 1869.